The UNIGE-HUG team's mouse study in Trends in Biotechnology demonstrates that embedding islets with vessel-forming cells in amniotic-membrane-derived Amniogel restores survival cues lost during isolation and enables self-assembly of microvessels before implantation. Grafts maintained normoglycemia for the full 100-day follow-up, outperforming non-vascularized controls. This is a small-scale preclinical experiment without reported randomization or blinding details, typical of early-stage transplant work rather than an RCT, and sample sizes remain unspecified. Prior encapsulation efforts, such as the 2019 Nature Medicine alginate-based devices that failed to prevent fibrosis long-term, highlight recurring vascular and immune barriers Amniogel partially sidesteps via pre-formed networks and slowed cytotoxic cell migration. The approach aligns with broader patterns where scaffold and delivery innovations—seen also in 2023 Cell Stem Cell reports on stem-cell-derived islets—yield faster functional gains than incremental improvements in insulin analogs. No conflicts of interest are disclosed. By shifting focus from perpetual drug refinement to scalable, GMP-compatible constructs, this work underscores how biomaterials can compress timelines toward a bioartificial pancreas far more than molecular discovery alone.